AbCellera Biologics Common Stock

AbCellera Biologics (ABCL) currently reports a common stock of $820M as of March 2026. That compares with $790M in the prior-year period — up 3.3% year over year. Use the charts on this page to explore AbCellera Biologics's common stock history and peer comparisons.

AbCellera Biologics's common stock increased from $790M to $820M — a 3.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AbCellera Biologics reported $820M in common stock as of March 2026. That compares with $790M in the prior-year period — up 3.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $820M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AbCellera Biologics, and consider following ABCL for alerts when major investors trade the stock.